Literature DB >> 21316112

Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders.

Irena Dujmovic1, Simone Mader, Kathrin Schanda, Florian Deisenhammer, Nebojsa Stojsavljevic, Jelena Kostic, Thomas Berger, Jelena Drulovic, Markus Reindl.   

Abstract

Neuromyelitis optica spectrum disorders (NMOSD) are associated with anti-aquaporin-4 autoantibodies (AQP4-IgG). Limited data is available on longitudinal cerebrospinal fluid (CSF) AQP4-IgG and their relation to disease activity and inflammatory parameters. AQP4-IgG titers were measured in matched longitudinal serum and CSF samples of 12 patients with NMOSD by an immunofluorescence assay and correlated with clinical parameters. CSF AQP4-IgG were present in patients with high serum titers and correlated with spinal MRI lesion length and CSF parameters. Clinical improvement was associated with a decrease in CSF, but not serum, AQP4-IgG titers. Thus, CSF AQP4-IgG were associated with clinical activity and neuroinflammation.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21316112     DOI: 10.1016/j.jneuroim.2011.01.007

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  21 in total

1.  Aquaporin 4 molecular mimicry and implications for neuromyelitis optica.

Authors:  Radhika A Vaishnav; Ruolan Liu; Joab Chapman; Andrew M Roberts; Hong Ye; Jovan D Rebolledo-Mendez; Takeshi Tabira; Alicia H Fitzpatrick; Anat Achiron; Mark P Running; Robert P Friedland
Journal:  J Neuroimmunol       Date:  2013-05-09       Impact factor: 3.478

Review 2.  The treatment of neuromyelitis optica.

Authors:  Markus C Kowarik; John Soltys; Jeffrey L Bennett
Journal:  J Neuroophthalmol       Date:  2014-03       Impact factor: 3.042

Review 3.  Brain-reactive antibodies and disease.

Authors:  B Diamond; G Honig; S Mader; L Brimberg; B T Volpe
Journal:  Annu Rev Immunol       Date:  2013       Impact factor: 28.527

Review 4.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

5.  Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.

Authors:  Simone Mader; Viktoria Gredler; Kathrin Schanda; Kevin Rostasy; Irena Dujmovic; Kristian Pfaller; Andreas Lutterotti; Sven Jarius; Franziska Di Pauli; Bettina Kuenz; Rainer Ehling; Harald Hegen; Florian Deisenhammer; Fahmy Aboul-Enein; Maria K Storch; Peter Koson; Jelena Drulovic; Wolfgang Kristoferitsch; Thomas Berger; Markus Reindl
Journal:  J Neuroinflammation       Date:  2011-12-28       Impact factor: 8.322

6.  Where Do AQP4 Antibodies Fit in the Pathogenesis of NMO?

Authors:  Makoto Kinoshita; Yuji Nakatsuji
Journal:  Mult Scler Int       Date:  2012-03-12

Review 7.  The B cell immunobiology that underlies CNS autoantibody-mediated diseases.

Authors:  Bo Sun; Melanie Ramberger; Kevin C O'Connor; Rachael J M Bashford-Rogers; Sarosh R Irani
Journal:  Nat Rev Neurol       Date:  2020-07-28       Impact factor: 44.711

Review 8.  Single-cell approaches to investigate B cells and antibodies in autoimmune neurological disorders.

Authors:  Alicia Zou; Sudarshini Ramanathan; Russell C Dale; Fabienne Brilot
Journal:  Cell Mol Immunol       Date:  2020-07-29       Impact factor: 22.096

9.  Detection of Antibodies against Human and Plant Aquaporins in Patients with Multiple Sclerosis.

Authors:  Aristo Vojdani; Partha Sarathi Mukherjee; Joshua Berookhim; Datis Kharrazian
Journal:  Autoimmune Dis       Date:  2015-07-26

10.  Evaluation of clinical interest of anti-aquaporin-4 autoantibody followup in neuromyelitis optica.

Authors:  Jean-Baptiste Chanson; Melissa Alame; Nicolas Collongues; Frédéric Blanc; Marie Fleury; Gabrielle Rudolf; Jérôme de Seze; Thierry Vincent
Journal:  Clin Dev Immunol       Date:  2013-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.